SENATE RESOLUTION 276--DESIGNATING JULY 15, 2019, AS ``NATIONAL LEIOMYOSARCOMA AWARENESS DAY'' AND THE MONTH OF JULY 2019 AS ``NATIONAL SARCOMA AWARENESS MONTH''; Congressional Record Vol. 165, No. 118
(Senate - July 15, 2019)
Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.
[Page S4825]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
SENATE RESOLUTION 276--DESIGNATING JULY 15, 2019, AS ``NATIONAL
LEIOMYOSARCOMA AWARENESS DAY'' AND THE MONTH OF JULY 2019 AS ``NATIONAL
SARCOMA AWARENESS MONTH''
Ms. STABENOW submitted the following resolution; which was referred
to the Committee on the Judiciary:
S. Res. 276
Whereas sarcoma is a rare type of cancer that arises in the
connective tissue of the body and accounts for approximately
1 percent of all newly diagnosed cancers;
Whereas the National Institutes of Health designates
sarcoma as a rare form of cancer, and sarcoma contains
approximately 70 different subtypes;
Whereas sarcomas are largely resistant to current
chemotherapy agents, immunotherapy agents, and radiation
therapies, posing a formidable challenge for researchers and
specialists;
Whereas sarcoma subtypes largely have not benefitted from
immunotherapies because of the complexity of the DNA,
genomes, and mutations associated with the many variations in
the sarcoma subtype landscape;
Whereas leiomyosarcoma (referred to in this preamble as
``LMS'') is a malignant, aggressive subtype of sarcoma
derived from smooth muscle cells typically of uterine,
gastrointestinal, or soft tissue origin, and can metastasize
to the bone, spine, brain, and liver;
Whereas the National Institutes of Health classifies LMS as
a rare disease, accounting for approximately 15 percent of
all sarcomas, and LMS itself encompasses at least 4 different
LMS subtypes;
Whereas LMS primarily affects adults without regard to
gender, research and clinical trials remain complicated, and
survival and longevity remain difficult;
Whereas multidisciplinary care coordination teams, because
of their expertise and experience, are critical to the health
of sarcoma and LMS patients;
Whereas sarcoma and LMS research will allow medical
professionals to improve the quality of care for affected
patients, lead to better clinical outcomes, and promote
longer survival for patients; and
Whereas increased education and awareness about sarcoma and
LMS will contribute to the well-being of the communities of
the United States: Now, therefore, be it
Resolved, That the Senate--
(1) designates July 15, 2019, as ``National Leiomyosarcoma
Awareness Day'';
(2) designates the month of July 2019 as ``National Sarcoma
Awareness Month'';
(3) recognizes the challenges faced by sarcoma and
leiomyosarcoma patients; and
(4) commends the dedication of organizations, volunteers,
researchers, and caregivers across the country working to
improve the quality of life of sarcoma and leiomyosarcoma
patients and their families.
____________________